138
Participants
Start Date
August 11, 2022
Primary Completion Date
March 14, 2025
Study Completion Date
March 13, 2026
Linezolid 600 mg
One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
Linezolid 1200 mg (QD)
Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
Linezolid 1200 mg (TIW)
Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
Bedaquiline 200 mg
Two 100mg tablets taken orally once daily in the morning during weeks 1-8
Bedaquiline 100 mg
One 100mg tablet taken orally once daily in the morning during weeks 9-26
Delamanid 300 mg
Six 50mg tablets taken orally once daily in the morning during weeks 1-26
Clofazimine 300 mg
Three 100mg capsules taken orally once daily in the morning during weeks 1-2
Clofazimine 100 mg
One 100mg capsule taken orally once daily in the morning during weeks 3-26
Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101), Johannesburg
Durban International CRS (Site ID: 11201), Durban
De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981), Cavite
University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792), Cape Town
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793), Cape Town
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802), Pathum Wan
Barranco CRS (Site ID: 11301), Lima
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784), Chiang Mai
Gaborone CRS (Site ID: 12701), Gaborone
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101), Rio de Janeiro
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730), Port-au-Prince
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022), Port-au-Prince
Rustenburg CRS (Site ID: 31684), Rustenburg
National Institute of Allergy and Infectious Diseases (NIAID)
NIH